YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study

Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 6f4e023d0a6861079157aa4fefafc5f9a283f5d1
First added on: Feb 19, 2025